secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001193125-23-133205
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 3.03, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta to merge with Dianthus in reverse merger; Dianthus holders to own 78.7% of combined firm
--------------------------------------------------------------------------------

- Dianthus stockholders will own ~78.7% of combined company; Magenta holders ~21.3%.
- Concurrent $70M private placement of Dianthus shares and pre-funded warrants closing pre-merger.
- Magenta holders get one CVR per share tied to net proceeds from legacy asset sales by Dec 31, 2023.
- Magenta CEO and board largely replaced; 6 of 8 board members designated by Dianthus.
- Termination fee of $13.3M payable by either party under specified conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523133205/0001193125-23-133205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523133205/d503643d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-133205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer